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Background: Antithrombotic prophylaxis with oral anticoagulation (OAC) substantially reduces
stroke and mortality in patients with atrial fibrillation (AF).
Hypothesis: Analysis of data in the Global Registry on Long-Term Antithrombotic Treatments in
Patients With Atrial Fibrillation (GLORIA-AF), an international, observational registry of patients
with newly diagnosed AF, can identify factors associated with treatment decisions and
outcomes.
Methods: Multivariable regression identified patient, physician, and temporal factors associated
with OAC prescription, compared with management with antiplatelet drugs or no antithrombo-
tic drugs in North American patients enrolled between November 2011 and February 2014.
Results: Of 3320 eligible patients (mean age, 71  11 years; 1879 males with CHA2DS2-VASc
≥1 and 1441 females with CHA2DS2-VASc ≥2), 79.3%, 12.5%, and 7.4% received OAC, antipla-
telet drugs, or no antithrombotic therapy, respectively. Of those prescribed OAC, 66.4%
received non–vitamin K antagonist oral anticoagulation and 24.5% received concomitant ther-
apy with antiplatelet drugs. Independent predictors of OAC therapy were nonparoxysmal AF
(odds ratio, 95% confidence interval: 2.02, 1.56–2.63), prior stroke/transient ischemic attack
(2.00, 1.37–2.92), specialist care (1.50, 1.04–2.17), more concomitant medications (1.47,
1.13–1.92), commercial insurance (1.41, 1.07–1.85), and heart failure (1.44, 1.07–1.92). Antipla-
telet drugs (0.18, 0.14–0.23), prior falls (0.41, 0.27–0.63), and prior bleeding (0.50, 0.35–0.72)
were inversely associated with OAC prescription.
Conclusions: In GLORIA-AF, 20% of the population comprising males with CHA2DS2-VASc ≥1
and females with CHA2DS2-VASc ≥2 did not receive OAC therapy. Patient characteristics asso-
ciated with a lower likelihood of OAC prescription were use of antiplatelet drugs, paroxysmal
pattern of AF, history of falls, and prior bleeding.
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1 | INTRODUCTION
Atrial fibrillation (AF) is a major cause of death and disability and is
associated with a 4- to 5-fold increase in the risk of ischemic
stroke.1,2 With appropriate patient selection, antithrombotic prophy-
laxis with oral anticoagulation (OAC) therapy reduces the risks of
stroke and all-cause mortality by approximately 64% and 26%,
respectively.3
For decades, vitamin K antagonists (VKAs) and antiplatelet drugs
were the only treatment choices for stroke prevention in patients with
AF. Although VKAs are superior to antiplatelet drugs for stroke
prevention,3,4 they have many food and drug interactions5 and require
frequent laboratory monitoring.6 The non-VKA oral anticoagulants
(NOACs) were developed to address some of these shortcomings. The
direct thrombin inhibitor dabigatran and factor Xa inhibitors apixaban,
edoxaban, and rivaroxaban are currently approved for use in the
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United States and Canada.7–10 Compared with warfarin, the NOACs
display similar efficacy for stroke prevention and have a generally
superior safety profile for bleeding risks, especially for intracranial
bleeds.7–10
As stroke-prevention therapies have advanced, criteria used to
select patients for OAC have also evolved. Current guidelines from the
American College of Cardiology/American Heart Association/Heart
Rhythm Society (ACC/AHA/HRS) recommend OAC for patients with a
CHA2DS2-VASc score ≥2.
11 These guidelines also state that in patients
with a CHA2DS2-VASc score of 1, any OAC, aspirin, or no antithrombo-
tic are reasonable. The Canadian Cardiovascular Society (CCS) currently
recommends OAC for patients with 1 CHA2DS2-VASc risk factor other
than female sex or vascular disease, and the European Society of Cardi-
ology (ESC) recommends OAC therapy for all males with a CHA2DS2-
VASc score ≥1 and females with a CHA2DS2-VASc score ≥2.
12,13 As
the global burden of AF has increased, patients are increasing in age,
number, and complexity, and there is variability in OAC prescription
practice that may, in part, reflect regional practice differences and
guidelines.14,15 Maximizing the guideline-based use of OAC is an impor-
tant goal. The recent IMProve treatment with AntiCoagulanTs in
patients with Atrial Fibrillation (IMPACT-AF) study demonstrated that
educational interventions were able to increase the appropriate use of
OAC in patients with AF, and that this was associated with a corre-
sponding reduction in the rate of stroke.16
Contemporary registries have reported rates of OAC among at-
risk patients ranging from 44% to 80%, and regional differences have
been observed in global registries.17–26 Although these registries have
demonstrated an increase over time in the number of patients receiv-
ing OAC and the proportion of those receiving a NOAC, there has
been limited exploration of clinical factors associated with decisions
to provide OAC treatment. Identification of factors inversely associ-
ated with OAC prescription could help focus targeted education or
inform further research, as appropriate. Therefore, the objective of
the present study was to identify patient, physician, and temporal fac-
tors associated with the stroke-prevention strategy prescribed for
North American patients in the Global Registry on Long-Term Oral
Antithrombotic Treatment in Patients With Atrial Fibrillation
(GLORIA-AF).
2 | METHODS
The Global Registry on Long-Term Antithrombotic Treatments in
Patients With Atrial Fibrillation (GLORIA-AF) is an international,
disease-based registry program enrolling patients with newly diag-
nosed nonvalvular AF who are at risk for stroke.27 This analysis com-
prises North American patients enrolled from November 2011 (1 year
following the approval of dabigatran in the United States and Canada)
through February 2014. The present analysis uses data from phase
2 of the GLORIA-AF Registry program.
The GLORIA-AF registry enrolls patients age ≥18 years with a
CHA2DS2-VASc score ≥1 and nonvalvular AF diagnosed at a maxi-
mum of 3 months prior to their baseline visit. This analysis excluded
females with a CHA2DS2-VASc score of 1.
12,13 The registry recruits
from a broad cross-section of clinical practice settings, including
academic and community hospitals as well as the offices of specialists
and primarycare providers. Recruiting centers were encouraged to
enroll consecutive patients to minimize selection bias. Exclusion cri-
teria included mechanical heart valves, valve disease expected to
require valve replacement during the course of the registry, >60 days
of VKA treatment for any indication in their lifetime, AF with a gener-
ally reversible cause, life expectancy <1 year, or an indication for OAC
other than AF.
Clinical and demographic characteristics, type of AF, and medical
therapies were recorded using standard electronic case-report forms.
Clinical data were collected using a validated web-based system.
2.1 | Statistical analysis
Demographic data are summarized by mean  SD and/or median and
interquartile ranges for continuous variables, and by frequencies and
percentages for categorical variables. Statistical analysis was per-
formed using SAS statistical software, version 9.4 (SAS Institute, Inc.,
Cary, NC).
In the primary analysis, patient characteristics and comorbidities,
prescriber characteristics, and temporal trends for use of OACs
(NOAC or VKA) vs antiplatelet drugs, or no therapy were compared
using multivariable logistic regression models. We selected variables a
priori based on potential factors that might be related to the decision
to provide OAC (Table 1). These variables were selected from those
collected in case-report forms and included the components of the
CHA2DS2-VASc and HAS-BLED scores, sociodemographic factors,
other major comorbidities, and patient characteristics believed to
potentially influence OAC prescription practices. In the secondary
analysis, a similar approach was used to compare patients receiving
NOAC vs VKA therapy.
Adjusted odds ratios (OR) and their 95% confidence intervals
(CI) were estimated using multivariable logistic regression models
based on the following preselected variables representing comorbid-
ities and demographic data: sex, medical history (heart failure [HF],
hypertension, diabetes mellitus [DM], prior stroke/transient ischemic
attack [TIA], prior bleeding, alcohol abuse, number of concomitant
medications above the cohort median, concomitant therapy with anti-
platelet drugs, liver disease, history of falls, cancer, chronic obstructive
pulmonary disease, peripheral artery disease, coronary artery disease,
smoking), insurance status (statutory or federal, commercial, or self-
pay), pattern of AF (paroxysmal vs persistent/permanent), specialty of
prescribing physician, and type of enrolling site. To analyze temporal
trends, the study period was divided into quartiles of approximately
equal length (November 14, 2011, to June 8, 2012; June 9, 2012, to
January 1, 2013; January 2, 2013, to July 27, 2013; and July
28, 2013, to February 19, 2014). To assess for nonlinear associations,
quadratic terms were entered into the model for continuous variables
(age, height, weight, and creatinine clearance).
For both descriptive and multivariable regression analyses, miss-
ing data points for continuous variables were excluded from the indi-
vidual analysis in question. Missing data points for categorical
variables (eg, medical history) were combined with the “No” category.
The actual numbers of missing data points are listed in the corre-
sponding tables.
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TABLE 1 Characteristics of study participants by prescribed stroke-prevention strategy
VKA, n = 885
(26.7)
NOAC, n = 1748
(52.7)
ASA, n = 414
(12.5)
None, n = 246
(7.4)
Overalla,b,
N = 3320
Demographics
CHA2DS2-VASc score 3.6  1.5 3.2  1.5 2.7  1.5 3.3  1.5 3.3  1.5
HAS-BLED score 1.5  0.9 1.4  0.9 2.0  0.8 1.2  0.8 1.5  0.9
Age, y 72  11 71  10 67  13 71  12 71  11
Weight, kg 91.8  26.7 91.3  24.0 88.6  23.9 85.6  23.6 90.6  24.7
CrCl, mL/min 84.0  46.0 89.8  42.7 95.8  50.5 80.0  38.7 88.2  44.7
Female sex 398 (45.0) 725 (41.5) 187 (45.2) 118 (48.0) 1441 (43.4)
Medical history
HF 246 (27.8) 316 (18.1) 62 (15.0) 40 (16.3) 669 (20.2)
HTN 749 (84.6) 1437 (82.2) 321 (77.5) 202 (82.1) 2732 (82.3)
DM 301 (34.0) 465 (26.6) 79 (19.1) 67 (27.2) 921 (27.7)
Prior stroke/TIA 136 (15.4) 233 (13.3) 18 (4.3) 27 (11.0) 422 (12.7)
Prior bleed 66 (7.5) 117 (6.7) 44 (10.6) 28 (11.4) 260 (7.8)
Alcohol ≥8 U/wk 52 (5.9) 136 (7.8) 44 (10.6) 12 (4.9) 246 (7.4)
No. of concomitant meds 4.1  1.9 3.8  2.0 3.4  2.0 3.5  2.1 3.9  2.0
Use of antiplatelet drugs 238 (26.9) 408 (23.3) 414 (100) 0 (0) 1080 (32.5)
Liver disease 18 (2.0) 20 (1.1) 9 (2.2) 7 (2.8) 54 (1.6)
Falls 48 (5.4) 71 (4.1) 27 (6.5) 20 (8.1) 171 (5.2)
Cancer 157 (17.7) 303 (17.3) 57 (13.8) 48 (19.5) 568 (17.1)
COPD/emphysema 109 (12.3) 166 (9.5) 39 (9.4) 20 (8.1) 338 (10.2)
PAD 43 (4.9) 81 (4.6) 20 (4.8) 19 (7.7) 167 (5.0)
CAD 259 (29.3) 479 (27.4) 96 (23.2) 70 (28.5) 919 (27.7)
Current smoking 80 (9.0) 112 (6.4) 46 (11.1) 27 (11.0) 267 (8.0)
Pattern of AF
Paroxysmal 558 (63.1) 1080 (61.8) 331 (80.0) 187 (76.0) 2175 (65.5)
Persistent 273 (30.8) 583 (33.4) 75 (18.1) 50 (20.3) 989 (29.8)
Permanent 54 (6.1) 85 (4.9) 8 (1.9) 9 (3.7) 156 (4.7)
Insurance
Government 596 (67.3) 1070 (61.2) 239 (57.7) 163 (66.3) 2088 (62.9)
Commercial 186 (21.0) 570 (32.6) 145 (35.0) 67(27.2) 974 (29.3)
None 103 (11.6) 108 (6.2) 30 (7.2) 16 (6.5) 258 (7.8)
Clinical care setting
Community hospital 79 (8.9) 124 (7.1) 65 (15.7) 15 (6.1) 285 (8.6)
University hospital 77 (8.7) 136 (7.8) 26 (6.3) 11 (4.5) 253 (7.6)
Specialist office 578 (65.3) 1250 (71.5) 242 (58.5) 156 (63.4) 2245 (67.6)
GP/PCP 136 (15.4) 211 (12.1) 79 (19.1) 57 (23.2) 485 (14.6)
Outpatient healthcare/anticoagulant clinic 15 (1.7) 27 (1.5) 2 (0.5) 7 (2.8) 52 (1.6)
Prescribers
Primary care 123 (13.9) 184 (10.5) 59 (14.3) 45 (18.3) 414 (12.5)
Cardiologist 734 (82.9) 1500 (85.8) 348 (84.1) 198 (80.5) 2802 (84.4)
Neurologist 21 (2.4) 52 (3.0) 2 (0.5) 1 (0.4) 77 (2.3)
Abbreviations: AF, atrial fibrillation; ASA, acetylsalicylic acid (aspirin); CAD, coronary artery disease; CHA2DS2-VASc, CHF, HTN, age >75 y, DM, stroke/
TIA, vascular disease, age 65–74 y, sex category (female); CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CrCl, creatinine
clearance; DM, diabetes mellitus; GP, general practitioner; HAS-BLED, HTN, abnormal renal and liver function, stroke, bleeding history or predisposition,
labile INR, elderly age (>65 years); HF, heart failure; HTN, hypertension; INR, international normalized ratio; NOAC, non-VKA oral anticoagulant; OAC, oral
anticoagulant; PAD, peripheral arterial disease; PCP, primary-care provider; SD, standard deviation; TIA, transient ischemic attack; VKA, vitamin K antago-
nist. Data are presented as n (%) or mean  SD.
a The numbers of patients from treatment groups do not add up to the overall column because 27 patients treated with an antiplatelet drug other than
ASA or a combination of OACs were not presented.
b For OAC treatment (VKA or NOAC), numbers of patients with missing/unknown values for the following characteristics are: HAS-BLED score (n = 211),
CrCl (n = 636), HF (n = 15), HTN (n = 1), prior stroke/TIA (n = 1), prior bleeding (n = 61), alcohol ≥8 U/wk (n = 102), liver disease (n = 16), prior falls
(n = 65), cancer (n = 7), COPD/emphysema (n = 12), PAD (n = 12), CAD (n = 28), and prescribers (n = 19). For non-OAC treatment (aspirin or none),
numbers of patients with missing/unknown values for the following characteristics are: HAS-BLED score (n = 59), CrCl (n = 157), HF (n = 3), HTN
(n = 2), prior stroke/TIA (n = 1), prior bleeding (n = 10), alcohol ≥8 U/wk (n = 32), liver disease (n = 6), prior falls (n = 21), cancer (n = 0), COPD/emphy-
sema (n = 2), PAD (n = 3), CAD (n = 12), and prescribers (n = 7).
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3 | RESULTS
From November 2011 through February 2014, 3320 eligible patients
were enrolled from 292 centers. A total of 2934 (88.4%) patients were
enrolled from 265 centers in the United States and 386 (11.6%) from
27 centers in Canada. The majority of patients were enrolled from
specialist offices (67.6%), followed by primary-care offices (14.6%).
Most prescribing physicians were cardiologists (84.4%). The mean age
of the study population was 71  11 years, the mean CHA2DS2-VASc
score was 3.3  1.5, and the mean HAS-BLED score was 1.5  0.9.
Patient demographics and medical history are summarized in Table 1,
grouped according to prescribed therapy.
Use of antithrombotic therapy according to age, stroke risk, and
bleeding risk is depicted in Figures 1 and 2. In patients with a
CHA2DS2-VASc score ≥2, the rate of OAC was significantly lower in
those with a HAS-BLED score of ≥3 compared with those with a HAS-
BLED score ≤2 (74.0% vs 83.0%, respectively; P < 0.0001). This was
accompanied by a significant increase in the proportion of patients
managed with aspirin alone (21.7% vs 9.3%, respectively; P < 0.0001).
The results of the multivariable models of factors associated
with the choice of OAC prescription as opposed to non-OAC
management (antiplatelet drugs or no antithrombotic treatment) are
displayed in Table 2 and in Supporting Information, Table 1, in the
online version of this article. Independent predictors of OAC therapy
prescription were nonparoxysmal AF, prior stroke/TIA, greater num-
ber of concomitant medications, commercial insurance coverage, a
history of HF, and care by a specialist. There was also a positive cor-
relation between increasing age and OAC prescription. Antiplatelet
drug use, history of falls, and prior bleeding were inversely associ-
ated with OAC. There was a significant, “U-shaped” relationship in
the odds of receiving OAC vs no OAC across the 4 time quartiles
(overall P = 0.004; see Supporting Information, Table 1, in the online
version of this article).
The results of the multivariable prediction models for the selec-
tion of NOAC as opposed to VKA therapy in the 2633 patients who
received OAC are presented in Table 3 and in Supporting Information,
Table 2, in the online version of this article. Having commercial insur-
ance coverage and being enrolled at a specialist's office were each sig-
nificantly associated with a greater likelihood of NOAC use. Factors
associated with VKA use included HF, lack of commercial insurance
coverage, DM, and additional therapy with antiplatelet drugs. There
was a significant “U-shaped” relationship in the odds of receiving
FIGURE 1 Prescribing patterns for NOAC, VKA, aspirin, or no antithrombotic according to HAS-BLED and CHA2DS2-VASc scores. Among the
3320 eligible patients, 273 patients missing HAS-BLED scores and/or 27 patients who were prescribed other treatments (eg, antiplatelet drugs
except aspirin or treatment combinations) were not included in the figure. Abbreviations: CHA2DS2-VASc, CHF, HTN, age >75 y, DM, stroke/TIA,
vascular disease, age 65–74 y, sex category (F); CHF, congestive heart failure; DM, diabetes mellitus; F, female; HAS-BLED, HTN, abnormal renal
and liver function, stroke, bleeding history or predisposition, labile INR, elderly age (>65 years); HTN, hypertension; INR, international normalized
ratio; NOAC, non-VKA oral anticoagulant; TIA, transient ischemic attack; VKA, vitamin K antagonist
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NOAC vs VKA across the 4 time quartiles (overall P < 0.0001; see
Supporting Information, Table 2, in the online version of this article).
4 | DISCUSSION
In this cohort of high-risk North American patients (males with a
CHA2DS2-VASc score ≥1 and females with a CHA2DS2-VASc
score ≥2) with newly diagnosed nonvalvular AF, 20% of the analysis
population did not receive OAC therapy. Nonparoxysmal AF, prior
stroke/TIA, more concomitant medications, commercial insurance
coverage, HF, being seen at a specialist office, and advanced age were
associated with use of OAC. Conversely, treatment with antiplatelet
drugs, history of falls, and prior bleeding were associated with a lower
likelihood of OAC. This analysis suggests that patient characteristics
and conditions affect selection of an antithrombotic treatment strat-
egy. This is the first study to examine patient, physician, and temporal
factors associated with the stroke-prevention strategy prescribed for
North American patients with AF.
OAC in our cohort (79.3%) is at the higher end of the range
reported in other contemporary registries. Differences in OAC rates
among registries may reflect different inclusion criteria; whereas other
major registries include all patients, GLORIA-AF includes patients with
a CHA2DS2-VASc score ≥1.
17,20,28 In a report from the US-based
Practice Innovation and Clinical Excellence (PINNACLE) registry
(enrollment January 2008 to December 2012), among patients with a
mean CHA2DS2-VASc score of 3.7, only 44.9% of patients received
OAC and 31.4% were placed on therapy with antiplatelet drugs.17
This registry sampled exclusively from cardiology practices and did
not report the components of the HAS-BLED score.
In a publication from the most recent cohort (2014–2015) of the
Global Anticoagulant Registry in the FIELD–Atrial Fibrillation
(GARFIELD-AF), among patients with a median CHA2DS2-VASc score
of 3.0, 71.1% were taking OAC and 16.6% were taking antiplatelet
drug monotherapy.20 In a 2015 report from the EURO-Observational
Research Programme on Atrial Fibrillation (EORP-AF) registry (enroll-
ment February 2012 to March 2013), OAC was prescribed to 79.8%
and 81.5% of females and males, respectively.28 Data from the
GARFIELD-AF registry indicate that appropriate OAC has increased
over time and this is largely driven by increased use of NOACs.20 The
most recent publication has highlighted factors underpinning the deci-
sion between VKA and NOAC. NOACs were chosen more often than
VKAs among men, the elderly (age >65 years), patients of Asian eth-
nicity, those with dementia, those using nonsteroidal anti-
inflammatory drugs, and current smokers. VKAs were chosen more
often than NOACs among patients with cardiac, vascular, and/or renal
comorbidities.
Differences in patient characteristics and the rates of medication
usage between North American patients and other patients in the
global GLORIA-AF registry program have been reported previously.26
Globally, 80% of patients with a CHA2DS2-VASc score ≥1 were pre-
scribed OAC and 12% were prescribed therapy with antiplatelet drugs
alone.19,26 North American patients make up 22.5% of the global
cohort and medication usage rates are similar to the overall global
trends. Rates of OAC were highest in Europe, where 90% of patients
received OAC and 6% were given antiplatelet drugs alone. Slightly
FIGURE 2 Stroke prevention strategy according to stroke risk.
Among the 3320 eligible patients, 3293 were included in this analysis
(27 patients treated with antiplatelet drugs except aspirin or
combinations of OACs were excluded). Abbreviations: CHA2DS2-
VASc, CHF, HTN, age >75 y, DM, stroke/TIA, vascular disease, age
65–74 y, sex category (F); CHF, congestive heart failure; DM, diabetes
mellitus; F, female; HTN, hypertension; M, male; NOAC, non-VKA oral
anticoagulant; OAC, oral anticoagulant; TIA, transient ischemic attack;
VKA, vitamin K antagonist
TABLE 2 Independent categorical predictors of OAC vs non-OAC
prescription
Adjusted OR
(95% CI)a,b P Valuec
Medical history
No/missing 1.00 (Ref ) —
HF 1.44 (1.07–1.92) 0.015
Prior stroke/TIA 2.00 (1.37–2.92) 0.0003
No. of concomitant meds > mediand 1.47 (1.13–1.92) 0.005
Prior bleed 0.50 (0.35–0.72) 0.0002
Use of antiplatelet drug 0.18 (0.14–0.23) <0.0001
History of falls 0.41 (0.27–0.63) <0.0001
Pattern of AF
Paroxysmal 1.00 (Ref ) —
Persistent/permanent 2.02 (1.56–2.63) <0.0001
Insurance
Statutory/federal 1.00 (Ref ) —
Commercial 1.41 (1.07–1.85) 0.016
Clinical care settinge
Community hospital 1.00 (Ref ) —
Specialist 1.50 (1.04–2.17) 0.032
Abbreviations: AF, atrial fibrillation; CI, confidence interval; HF, heart fail-
ure; OAC, oral anticoagulant; OR, odds ratio; Ref, reference; TIA, transient
ischemic attack.
a OR >1 favors OAC; OR <1 favors antiplatelet drug or no OAC.
b This analysis included 3313 patients.
c See Supporting Information, Table 1, in the online version of this article
for the full information and results of the associated multivariable predic-
tion model.
d Median no. of concomitant medications excluding antithrombotic drugs.
e There is a trend for greater likelihood of OAC in the university hospital
clinical setting (OR: 1.66, 95% CI: 0.97–2.83, P = 0.063).
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higher rates of OAC use in Europe may be driven by the fact that ESC
guidelines more strongly suggest OAC for patients with a single
CHA2DS2-VASc risk factor (other than sex) than do guidelines from
the United States.11,13
In this study, use of antiplatelet drugs, history of falls, prior bleed-
ing, and paroxysmal AF (vs persistent/permanent AF) were identified
as potential reasons for not prescribing OAC. In the present
cohort, approximately 1 in 4 patients who received OAC also received
antiplatelet drugs. The practice of combining antiplatelet drugs and
OAC has been associated with increased bleeding without reduction
in thrombotic outcomes.29,30 Additionally, discontinuing therapy with
antiplatelet drugs is one of the modifiable elements of the HAS-BLED
score.31 Outside of specific transient indications such as recent acute
coronary syndrome or coronary stent, prescribing concomitant ther-
apy with antiplatelet drugs in patients receiving OAC for AF should be
avoided.12,13
Falls remain a controversial risk factor for bleeding in patients
with AF;32–34 however, there is no clear evidence to support falls or a
predisposition thereto as a contraindication to OAC. The ESC guide-
lines recommend withholding therapy only in patients with a predis-
position to severe, uncontrolled falls.13
It is not surprising that patients in this cohort with a history of
bleeding were significantly less likely to receive OAC. The approach to
stroke prevention in patients with AF and a history of bleeding is chal-
lenging. Observational data suggest that in patients who have bled on
OAC, resumption of OAC after an appropriate interval impacts posi-
tively on stroke and mortality, even after an intracranial bleed.35–37
However, many questions remain with respect to the safety, timing,
and circumstances under which to initiate or resume OAC after a
bleeding event, and randomized studies are required to provide
guidance.13
Bleeding risk also influenced choice of stroke prevention strategy
in this cohort. Among patients at higher risk of stroke (ie, CHA2DS2-
VASc score ≥2), those at high risk of bleeding (ie, HAS-BLED score
≥3) were significantly less likely to receive OAC and more likely to
receive antiplatelet drugs than those at low risk of bleeding (ie, HAS-
BLED score ≤2; Figure 1). The superiority of OAC over therapy with
antiplatelet drugs for stroke prevention has been well-established in a
meta-analysis.3 The net clinical benefit (balance of stroke and bleed-
ing) of OAC over therapy with antiplatelet drugs has been demon-
strated in patients with AF who have additional risk factors for stroke,
including those with higher HAS-BLED scores.38,39 We advocate that
a high HAS-BLED score should not preclude the use of OAC; rather, it
should help identify patients who need closer follow-up, addressing
reversible factors for bleeding.13,40
Patients with paroxysmal AF were less likely to receive OAC than
those with persistent or permanent AF. However, the balance of cur-
rent evidence suggests that although patients with permanent AF
appear to have a higher risk of stroke, patients with each of the 3 pat-
terns of “clinical” AF (permanent, persistent, or paroxysmal) who have
additional stroke risk factors have a sufficiently high risk of stroke to
warrant consideration of OAC.41–44 This position is supported by the
AHA/ACC/HRS, ESC, and CCS guidelines, each of which recommend
against taking the clinical pattern of AF into account when risk-
stratifying patients with AF.11–13 Patients with paroxysmal AF were
included in all major trials of OAC.7–10
In our secondary analysis, approximately two-thirds of patients
who started OAC therapy received 1 of the NOACs. NOAC use (over
VKA) was predicted by having commercial insurance coverage and
care from a specialist. Factors that predicted use of a VKA included
HF, lack of insurance coverage, DM, and additional therapy with anti-
platelet drugs. We found significant “U-shaped” relationships in the
odds of receiving OAC and the odds of receiving a NOAC across the
4 time quartiles in our study. These relationships could reflect interac-
tions between a number of physician, patient, and payer factors that
impacted prescribing patterns for OACs and NOACs over this time-
frame. Overall, our analysis supports the notion that, after an initial
latency period, NOAC use is beginning to overtake VKA use in North
America and throughout the world.17–20,45
4.1 | Study limitations
This study enrolled patients from 413 centers in Canada and the
United States, encompassing a wide range of healthcare settings in
order to represent a broad cross-section of patients treated. Sites
were directed by protocol to enroll patients consecutively; however,
because GLORIA-AF is not population-based, it may not completely
represent the entirety of the AF population. The observed treatment
patterns are affected by the sites composing the sample.
Most patients (84.4%) had a cardiologist as the prescribing physi-
cian and most (67.6%) were seen in a specialist office. This may have
affected the number of patients receiving OAC and increased the pro-
portion receiving a NOAC. It is worth noting that these data were
TABLE 3 Independent categorical predictors of NOAC vs VKA
prescription
Adjusted OR
(95% CI)a,b P Valuec
Medical history
No/missing 1.00 (Ref ) —
HF 0.55 (0.44–0.70) <0.0001
DM 0.78 (0.62–0.99) 0.037
Use of additional antiplatelet drug 0.79 (0.63–0.99) 0.043
Insurance
Statutory/federal 1.00 (Ref ) —
Commercial 1.72 (1.34–2.22) <0.0001
Self-pay/no coverage/unknown 0.64 (0.45–0.92) 0.015
Clinical care settingd
Community hospital 1.00 (Ref ) —
Specialist office 1.61 (1.12–2.32) 0.010
Abbreviations: CI, confidence interval; DM, diabetes mellitus; GP, general
practitioner; HF, heart failure; NOAC, non-VKA oral anticoagulant; OR,
odds ratio; PCP, primary-care provider; Ref, reference; VKA, vitamin K
antagonist.
a OR >1 favors NOAC; OR <1 favors VKA.
b This analysis included 2633 patients.
c See Supporting Information, Table 2, in the online version of this article
for the full information and results of the associated multivariable predic-
tion model.
d There is a trend for greater likelihood of NOAC use in the GP/PCP clini-
cal setting (OR: 1.52, 95% CI: 0.98–2.37, P = 0.063).
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collected before the arrival of target-specific reversal agents for
NOACs; it remains unknown whether the availability of reversal
agents would change decisions to offer OAC and/or to offer a NOAC
over VKA.
5 | CONCLUSION
In this North American cohort of patients with AF, one-fifth of the
study population, comprising males with a CHA2DS2-VASc score ≥1
and females with a CHA2DS2-VASc score ≥2, did not receive OAC.
CHADS2 risk factors generally predicted OAC; however, use of anti-
platelet drugs, a history of falling, prior bleeding, and paroxysmal AF
were identified as potential reasons to not provide OAC.
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